Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Astrotech commercializes advanced mass spectrometry technology through subsidiaries focused on security (1st Detect), agriculture (AgLAB), and medical diagnostics (BreathTech). Its BreathTech subsidiary is developing a breath analysis tool for infection screening, including COVID-19 and pneumonia, but there is no public evidence of late-stage clinical development or regulatory approval for therapeutic or diagnostic products as of 2025. The company’s historical biotech efforts (via Astrogenetix) included microgravity-based vaccine discovery but these appear dormant in recent disclosures
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Astrotech.